Advertisement

Organisation › Details
Transgene S.A. (Euronext: TNG)
Transgene is a France-based biopharmaceutical company focused on the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The Company has four compounds in Phase II clinical trials: TG4010, JX594/TG6006, TG4001/RG3484 and TG4040 and one compound in Phase I clinical trial: TG4023. Transgene has entered into strategic collaborative agreements for the development of two of its immunotherapy products: - An option agreement with Novartis for an exclusive license to develop TG4010 for the treatment of various cancers, including non small cell lung cancer (NSCLC) - An in-licensing agreement with US-based Jennerex Biotherapeutics, Inc., to develop and market JX594 (JX594/TG6006), an oncolytic product. Transgene has bio-manufacturing capacities for viral-based vectors. *
![]() |
Start | 1979-01-01 established |
Group | Mérieux (Group) | |
![]() |
Industry | therapeutic vaccine |
Industry 2 | immunotherapy | |
![]() |
Person | Archinard, Philippe (Institu Mérieux 202101– EVP Technological Innovation + Scientific Partnerships before Transgene) |
![]() |
Region | Strasbourg |
Country | France | |
Street | Boulevard Gonthier d’Andernach Parc d’Innovation d’Illkirch | |
City | 67405 Illkirch | |
Tel | +33-3-8827-9100 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2006-12-31) |
Currency | EUR | |
Annual sales | 28,019,000 (revenues, total (2007) 2007-12-31) | |
Profit | -5,521,000 (2007-12-31) | |
Cash | 84,100,000 (2014-09-30) | |
* Document for �About Section�: | ||
Record changed: 2020-12-04 |
Advertisement

More documents for Mérieux (Group)
- [1] Mérieux Equity Partners S.A.S.. (12/8/20). "Press Release: Cell-Easy Announces the Completion of a Financing Round to Accelerate Its Growth Trajectory in the Cell Therapy Sector, With Merieux Equity Partners as Lead Investor and Reference Shareholder". T...
- [2] Transgene S.A.. (12/3/20). "Press Release: Transgene Appoints Hedi Ben Brahim as Chairman and Chief Executive Officer". Strasbourg....
- [3] Transgene S.A.. (5/4/20). "Press Release: Vaxxel Acquires Transgene’s DuckCelt-T17 Cell Line to Develop Industrial-scale Vaccines against Respiratory Viruses". Lyon & Strasbourg....
- [4] GeNeuro S.A.. (1/31/20). "Press Release: GeNeuro Announces Successful €17.5 Million Private Placement [Not for United States, Australia, Canada, Japan, South Africa or any other Jurisdiction where Unlawful]". Geneva....
- [5] Mérieux Equity Partners S.A.S.. (1/8/20). "Press Release: Mérieux Equity Partners Successfully Completes the Fundraising of Mérieux Participations 3". Lyon....
- [6] Keranova S.A.. (9/10/19). "Press Release: Keranova Raises €24m in Second Round of Financing". Saint-Etienne & Lyon....
- [7] Transgene S.A.. (7/2/19). "Press Release: Success of Transgene’s €48.7 Million Rights Issue [This document must not be distributed, directly or indirectly, in the United States of America, Australia, Canada or Japan]". Strasbourg....
- [8] Transgene S.A.. (6/14/19). "Press Release: Transgene Launches a Rights Issue for an Amount of up to €50 Million [This document must not be distributed, directly or indirectly, in the United States of America, Australia, Canada or Japan]". Strasbourg....
- [9] bioMérieux S.A.. (6/6/19). "Press Release: bioMérieux Increases Its Holding in Hybiome from 54% to 67%". Marcy l’Étoile....
- [10] Transgene S.A.. (5/2/19). "Press Release: Transgene and AstraZeneca Enter into a Collaboration and Exclusive License Option Agreement for Innovative Invir.IO based Armed Oncolytic Immunotherapies". Strasbourg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top